| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
SF-22 targets the neuropeptide Y receptor Y2R, a G protein-coupled receptor involved in various physiological processes including appetite regulation, anxiety, and pain modulation. The compound acts as a Y2R antagonist with an IC50 of 750 nM. By blocking Y2R signaling, SF-22 may modulate neuropeptide Y-mediated effects in the central nervous system. Its ability to cross the blood-brain barrier makes it suitable for studying neurological disorders.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that SF-22 is a potent antagonist of the neuropeptide Y receptor Y2R with an IC50 of 750 nM. This activity indicates effective inhibition of Y2R-mediated signaling. The compound's ability to cross the blood-brain barrier and its potential anti-inflammatory activity make it a valuable tool for neurological research. Detailed in vitro activity data, including receptor binding affinity and functional assay results, are not extensively documented in the available literature.
|
| ln Vivo |
In vivo activity of SF-22 is attributed to its ability to cross the blood-brain barrier and antagonize Y2R in the central nervous system. It has potential anti-inflammatory activity and may be useful for studying diseases associated with neurological disorders. By modulating neuropeptide Y signaling, SF-22 may affect appetite, anxiety, pain, and other physiological processes. Detailed in vivo efficacy data from animal models are not extensively documented in the available literature.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for SF-22 typically involves measuring its binding affinity and antagonistic activity at the neuropeptide Y receptor Y2R. Competitive binding assays using radiolabeled ligands and membrane preparations from cells expressing Y2R are performed to determine binding affinity. Functional assays measuring inhibition of Y2R-mediated signaling, such as cAMP accumulation or calcium mobilization, are used to confirm antagonistic activity. IC50 values are determined from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for SF-22 are conducted using cell lines expressing the neuropeptide Y receptor Y2R. Cells are treated with the compound at various concentrations, and Y2R activation is measured by assessing downstream signaling pathways such as cAMP production or calcium mobilization. The compound's ability to inhibit Y2R-mediated responses to neuropeptide Y is evaluated. Standard protocols include appropriate positive controls such as known Y2R antagonists and vehicle controls.
|
| Animal Protocol |
In vivo animal studies for SF-22 would typically be conducted using mouse or rat models of neurological disorders. Animals would be administered the compound via oral or intraperitoneal routes, and efficacy would be evaluated by measuring behavioral outcomes, inflammatory markers, and histopathological changes. Pharmacokinetic parameters would be determined from plasma and brain tissue samples. However, detailed in vivo protocols and efficacy data are not available from the search results.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of SF-22 include its ability to cross the blood-brain barrier. The compound has a molecular weight of 470.58 and a molecular formula of C28H26N2O3S. Solubility includes DMSO at 100 mg/mL (212.5 mM). Purity is reported as 99.17%. Storage recommendations include powder at -20°C for 3 years and in solvent at -80°C for 1 year. Detailed pharmacokinetic parameters are not extensively documented.
|
| Toxicity/Toxicokinetics |
Toxicity information for SF-22 is limited. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
SF-22 is a potent, blood-brain barrier permeable neuropeptide Y receptor Y2R antagonist with an IC50 of 750 nM. It has potential anti-inflammatory activity and is used for the study of neurological disorders. The compound has a molecular weight of 470.58 and formula C28H26N2O3S. It is also known as 3-[(2,5-dimethylphenyl)sulfamoyl]-4-methyl-N-(2-phenylphenyl)benzamide. It is intended for research use only.
|
| Molecular Formula |
C28H26N2O3S
|
|---|---|
| Molecular Weight |
470.58
|
| Exact Mass |
470.166
|
| CAS # |
824981-55-7
|
| PubChem CID |
2223246
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.869
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
773
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NC1=CC=CC=C1C2=CC=CC=C2)C3=CC=C(C)C(S(=O)(NC4=CC(C)=CC=C4C)=O)=C3
|
| InChi Key |
BWWPVIRXNOWQSI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H26N2O3S/c1-19-13-14-20(2)26(17-19)30-34(32,33)27-18-23(16-15-21(27)3)28(31)29-25-12-8-7-11-24(25)22-9-5-4-6-10-22/h4-18,30H,1-3H3,(H,29,31)
|
| Chemical Name |
3-[(2,5-dimethylphenyl)sulfamoyl]-4-methyl-N-(2-phenylphenyl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~125 mg/mL (~265.63 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1250 mL | 10.6252 mL | 21.2504 mL | |
| 5 mM | 0.4250 mL | 2.1250 mL | 4.2501 mL | |
| 10 mM | 0.2125 mL | 1.0625 mL | 2.1250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
